Alexion Pharmaceuticals (NASDAQ:ALXN) has been the undisputed champion of the Top 5 list, having claimed the No. 1 spot for six out of the past seven issues! And with the company’s stunning earnings announcement on Feb. 10, it’s easy to see why. Thanks to booming sales of Soliris, the company’s rare-blood-disorder treatment, the company reported blowout operating results for last year’s fourth quarter.
Sales climbed 46%, to $227.6 million, and earnings soared 89% year-over-year, to $48.2 million. Adjusted earnings per share came in at $0.41, which topped the consensus estimate by 21%! Plus, the company is similarly bullish about this year.
The company expects 2012 sales in the range of $1.04 billion to $1.07 billion. Its adjusted earnings guidance falls in the range of $1.60 to $1.70 per share. Alexion’s guidance tops the Street view of $1.67 per share on revenues of $1.04 billion.